Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £379 | £310 | £177 | £67 |
| - Cash | £13 | £22 | £13 | £14 |
| + Debt | £60 | £46 | £31 | £10 |
| Enterprise Value | £426 | £334 | £195 | £64 |
| Revenue | £21 | £34 | £22 | £34 |
| % Growth | -38.2% | 57.3% | -35.6% | – |
| Gross Profit | £4 | £21 | £9 | £21 |
| % Margin | 20.3% | 61.3% | 42.6% | 61.1% |
| EBITDA | -£23 | -£6 | -£21 | -£10 |
| % Margin | -109.3% | -19% | -97.3% | -28.9% |
| Net Income | -£29 | -£11 | -£25 | -£16 |
| % Margin | -138.2% | -32.6% | -113.6% | -46.6% |
| EPS Diluted | -0.006 | -0.002 | -0.007 | -0.006 |
| % Growth | -165.2% | 64.6% | -12.1% | – |
| Operating Cash Flow | -£21 | -£8 | -£22 | -£11 |
| Capital Expenditures | -£2 | -£2 | -£2 | -£2 |
| Free Cash Flow | -£23 | -£9 | -£23 | -£13 |